Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371628 | 0.89 | TACR1 (0.61) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL12371604 | 0.87 | CTSS (0.60) | CTSKCTSLCTSBCTSSHDAC8 | |
| SCHEMBL7762796 | 0.85 | CTSL (0.74) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL4655258 | 0.81 | TACR1 (0.78) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL13619740 | 0.81 | MAPT (0.51) | ALDH1A1 | |
| SCHEMBL25699716 | 0.79 | TACR1 (0.70) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL4070768 | 0.79 | CTSL (0.76) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL17643540 | 0.79 | CTSL (0.76) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL7971421 | 0.78 | TACR1 (1.00) | TACR1CTSKCTSLCTSBCTSS | |
| SCHEMBL19807564 | 0.78 | TACR1 (0.72) | TACR1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | CTSB, CTSS, CTSV | TACR1 679/4885CTSK 11/4885CTSL 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.